Dawn has been a member of R&D teams at Illumina and 454 Life Sciences, as well as several biotech startups. Dawn was instrumental in the development and commercialization of products across a range of technologies including microarrays, immunoassays, and Next Generation Sequencing. While at 454 Life Sciences she was a member of the development team that launched the FLX+ and GS Junior Next Generation Sequencing Systems. She has built and led R&D teams from product concept to commercialization. Her experience in customer driven product development has led to successful launch of life science products in both small and large companies. Dawn is currently the Director of R&D at Shoreline Biome, a leading edge company developing microbiome kits and software to advance the use of NGS in microbiome translational research. Dawn received a B.S in biology from Wilkes University and an M.S. in cellular and molecular biology from the University of New Haven.